Prediction of Abdominal Aortic Aneurysm Shrinkage After Stent-placement With Artificial Intelligence
Launched by RIJNSTATE HOSPITAL · Feb 1, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain factors can help predict whether an abdominal aortic aneurysm (AAA) will shrink after a stent is placed. An AAA is when the main artery in your belly becomes enlarged, which can be dangerous. The researchers want to develop a model using artificial intelligence to better understand what leads to successful treatment outcomes one year after the stent placement.
To be eligible for this study, participants must be at least 18 years old and have undergone a specific type of procedure called elective infrarenal endovascular aneurysm repair (EVAR) for an unruptured AAA. They should have had a successful procedure and be using certain approved stent devices. Participants will need to have follow-up imaging done at least a year after their procedure to help evaluate the results. This study is currently recruiting and welcomes all genders. If you join, you can expect to contribute to important research that may improve future treatments for AAA.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years;
- • Elective, initially technically successful (as described by the ESVS guidelines11), infrarenal EVAR for unruptured infrarenal AAA;
- • Implanted endograft is a Gore Excluder, Medtronic Endurant, Cook Zenith, Cordis Incraft, Endologix AFX, Jotec E-Tegra, or Vascutek Anaconda endograft;
- • Follow-up of the AAA of at least one year with imaging of the same modality as the preoperative imaging;
- • Axial reconstructions of preoperative CT angiography available, preferably in the arterial phase and with 3 mm or smaller slice thickness.
- Exclusion Criteria:
- • Patients with ruptured or symptomatic AAA;
- • Patients that were treated with fenestrated or branched endografts, iliac branched devices, non-CE marked devices within trial setting, other endografts (EVAS cases) or chimney procedures;
- • Acute procedures;
- • Reintervention before one year follow-up;
- • Revision cases after previous open or endovascular aneurysm repair of an AAA;
About Rijnstate Hospital
Rijnstate Hospital is a leading healthcare institution based in the Netherlands, dedicated to providing high-quality patient care and advancing medical research. With a strong emphasis on innovation and collaboration, Rijnstate Hospital actively engages in clinical trials to explore new treatment options and improve patient outcomes across various medical fields. The hospital's multidisciplinary approach integrates the expertise of healthcare professionals, researchers, and academic partners, ensuring rigorous scientific methodologies and adherence to ethical standards. Committed to enhancing the health and well-being of the communities it serves, Rijnstate Hospital plays a pivotal role in the advancement of medical knowledge and the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arnhem, , Netherlands
Enschede, , Netherlands
Groningen, , Netherlands
Amsterdam, , Netherlands
Arnhem, Non Us/Canada, Netherlands
Stockholm, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported